BioNTech SE Chief Executive Officer Ugur Sahin filed an amended insider ownership report that updates his indirect holdings in the company. The filing shows 39,218,111 ordinary shares are held by Medine GmbH, an entity of which he is the sole shareholder.
Within this amount, 106,721 ordinary shares are held for the benefit of an individual under a trust arrangement. Medine GmbH has voting power, but not dispositive power, over those trust shares. Sahin may be deemed to beneficially own the ordinary shares held by Medine GmbH, and the amendment does not report any new purchases or sales.
BioNTech SE reported positive Phase 2 data for its HER2‑targeted antibody-drug conjugate trastuzumab pamirtecan (BNT323/DB‑1303) in 145 patients with advanced or metastatic HER2‑expressing endometrial cancer whose disease had progressed after prior therapies.
The primary endpoint was met, with a confirmed objective response rate of 49.3% in 73 centrally HER2‑tested patients previously treated with checkpoint inhibitors and 47.9% in all centrally tested patients, alongside a median progression‑free survival of 8.1 months. Responses were seen across all HER2 expression levels, including lower HER2 tumors, and safety was described as manageable, with grade ≥3 treatment‑related adverse events in 46.9% of patients and grade ≥3 interstitial lung disease or pneumonitis in 4.8%. Trastuzumab pamirtecan has U.S. FDA Fast Track and Breakthrough Therapy designations for endometrial cancer, and a global Phase 3 confirmatory trial is ongoing with plans for a biologics license application in 2026, subject to regulatory feedback.
BioNTech SE has called a virtual Annual General Meeting for May 15, 2026, where shareholders will vote electronically via an Investor Portal. The meeting will present 2025 financial statements and a proposal to carry forward the EUR 6,901,677,892.10 balance sheet profit in full.
Key resolutions include expanding the Supervisory Board from six to eight members, re-electing three current members, and electing two new oncology and clinical-development specialists. Shareholders will also vote on extending authorization to hold virtual AGMs and replacing the remaining 2025 capital authorization with a new Authorized Capital 2026 of up to EUR 129,513,743 (50% of current share capital).
The agenda further covers approval of the 2025 compensation report, appointment of EY as auditor for 2026, and a domination and profit-and-loss transfer agreement with wholly owned subsidiary BioNTech Discovery GmbH. As of the notice date, share capital comprises 259,027,487 registered shares and 252,884,261 voting shares after treasury holdings.
BioNTech SE filed Amendment No. 1 to its Form 20-F to correct a typographical error in the date of EY’s audit opinions, changing them from March 10, 2025 to March 10, 2026 and updating the most recent practicable ordinary share count to 252,884,261.
The amendment does not change any financial statements or other disclosures for the year ended December 31, 2025. EY issued unqualified opinions on the consolidated IFRS financial statements and on internal control over financial reporting as of December 31, 2025.
The audited financials include €2.0 billion of collaboration revenue from COVID-19 vaccine sales, €0.6 billion of revenue from the Bristol-Myers Squibb collaboration, and business combinations such as the Biotheus and CureVac acquisitions with significant recognized intangible assets.
BioNTech SE filed an initial insider ownership report for director Nicola Claire Blackwood on Form 3. The filing identifies her role as a director and, in the data provided, does not report any equity transactions or derivative positions, serving mainly as a baseline disclosure of her status as an insider.
BioNTech SE director Anja Morawietz has filed an initial ownership report showing a modest equity stake in the company. The filing lists beneficial ownership of 200 ordinary shares held directly and an additional 40 ordinary shares held indirectly by her immediate family, as described in the footnote. This Form 3 does not report any recent share purchases or sales; it simply establishes her current holdings as she becomes a reporting insider.
BioNTech SE director Rudolf Staudigl filed an initial ownership report showing he holds 400 Ordinary Shares of the company. These shares are reported as held directly, and the filing does not list any recent purchase, sale, or other transaction activity, only the existing position.
BioNTech SE Chief Executive Officer Ugur Sahin filed an initial ownership report detailing his direct, indirect and derivative interests in the company’s ordinary shares. The filing shows indirect ownership of 40,132,788 ordinary shares held through Medine GmbH, which he wholly owns and may be deemed to beneficially own. It also lists 858,209 ordinary shares held directly.
In addition, Sahin holds several option and phantom option awards and performance share units tied to BioNTech ordinary shares, with various exercise prices and expiration dates extending to 2035. These awards generally vest in equal annual installments over four years and are subject to performance-based and other conditions.
BioNTech SE filed an initial beneficial ownership report for Chief Financial Officer Ramon Zapata Gomez on Form 3. This filing formally registers him as an officer subject to insider reporting rules. The available data shows no transactions or derivative positions reported in this Form 3 excerpt.
BioNTech SE officer Ryan James Timothy Patrick filed an initial ownership report showing existing equity awards and share holdings. He holds options over 25,459 and 8,838 ordinary shares with exercise prices of EUR 75.91 and EUR 93.35 that vest annually over four years and become exercisable four years after grant, subject to performance and other conditions. He also holds 11,047 performance share units, plus restricted stock units over 740 and 750 ordinary shares that vest in equal annual installments over four years with a four-year waiting period. In addition, he directly owns 4,795 ordinary shares, including 3,990 held jointly with his spouse.